Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003
Status:
Terminated
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of multiple
intravenous (IV) infusions of BIIB092 in participants with Progressive Supranuclear Palsy
(PSP). The study will also assess the pharmacodynamic (PD) effects of BIIB092 on
cerebrospinal fluid (CSF) N-terminal tau, pharmacokinetics (PK), and immunogenicity of
BIIB092 in participants with PSP.